Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Goodwill & Intangibles: 2021-2025

Historic Goodwill & Intangibles for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Sep 2025 value amounting to $15.5 million.

  • Kiniksa Pharmaceuticals International's Goodwill & Intangibles fell 6.06% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year decrease of 6.06%. This contributed to the annual value of $16.2 million for FY2024, which is 18.75% down from last year.
  • Kiniksa Pharmaceuticals International's Goodwill & Intangibles amounted to $15.5 million in Q3 2025, which was down 1.59% from $15.8 million recorded in Q2 2025.
  • Kiniksa Pharmaceuticals International's Goodwill & Intangibles' 5-year high stood at $20.0 million during Q1 2021, with a 5-year trough of $15.5 million in Q3 2025.
  • Its 3-year average for Goodwill & Intangibles is $17.4 million, with a median of $16.8 million in 2024.
  • Data for Kiniksa Pharmaceuticals International's Goodwill & Intangibles shows a maximum YoY dropped of 18.75% (in 2024) over the last 5 years.
  • Kiniksa Pharmaceuticals International's Goodwill & Intangibles (Quarterly) stood at $20.0 million in 2021, then remained steady at $20.0 million in 2022, then remained steady at $20.0 million in 2023, then dropped by 18.75% to $16.2 million in 2024, then declined by 6.06% to $15.5 million in 2025.
  • Its last three reported values are $15.5 million in Q3 2025, $15.8 million for Q2 2025, and $16.0 million during Q1 2025.